Alzheimer's disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients' genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with poor response to the drug. In a sample of 415 AD cases, we found evidence of association between rs1080985 and response to donepezil after 6 months of therapy (OR [95% CI]: 1.74 [1.01-3.00], p = 0.04). Rs1080985 might be useful as predictor of poor response to short-term donepezil treatment. © 2012 - IOS Press and the authors.
Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients / D., Albani; F., Martinelli Boneschi; G., Biella; G., Giacalone; S., Lupoli; F., Clerici; L., Benussi; R., Ghidoni; D., Galimberti; R., Squitti; S., Mariani; A., Confaloni; Bruno, Giuseppe; C., Mariani; E., Scarpini; G., Binetti; G., Magnani; M., Franceschi; G., Forloni. - In: JOURNAL OF ALZHEIMER'S DISEASE. - ISSN 1387-2877. - STAMPA. - 30:4(2012), pp. 745-749. [10.3233/jad-2012-112123]
Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in alzheimer's disease patients
BRUNO, Giuseppe;
2012
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients' genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with poor response to the drug. In a sample of 415 AD cases, we found evidence of association between rs1080985 and response to donepezil after 6 months of therapy (OR [95% CI]: 1.74 [1.01-3.00], p = 0.04). Rs1080985 might be useful as predictor of poor response to short-term donepezil treatment. © 2012 - IOS Press and the authors.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
